41. Khorchid A, Halwani R, Wainberg MA, Kleiman L (2002) Role of RNA in facilitating Gag/Gag-Pol interaction. J Virol 76: 4131–4137. 42. Crist RM, Datta SA, Stephen AG, Soheilian F, Mirro J, et al. (2009) Assembly properties of human immunodeficiency virus type 1 Gag-leucine zipper chimeras: implications for retrovirus assembly. J Virol 83: 2216–2225. 43. Zhang Y, Qian H, Love Z, Barklis E (1998) Analysis of the assembly function of the human immunodeficiency virus type 1 gag protein nucleocapsid domain. J Virol 72: 1782–1789. 44. Go¨ttlinger HG, Dorfman T, Sodroski JG, Haseltine WA (1991) Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A 88: 3195–3199. 45. VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, et al. (2001) Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci U S A 98: 7724–7729. 46. Bieniasz PD (2009) The cell biology of HIV-1 virion genesis. Cell Host Microbe 5: 550–558. 47. Strack B, Calistri A, Craig S, Popova E, Go¨ttlinger HG (2003) AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114: 689–699. 48. Ott DE, Coren LV, Gagliardi TD, Nagashima K (2005) Heterologous late- domain sequences have various abilities to promote budding of human immunodeficiency virus type 1. J Virol 79: 9038–9045. 49. Strack B, Calistri A, Go¨ttlinger HG (2002) Late assembly domain function can exhibit context dependence and involves ubiquitin residues implicated in endocytosis. J Virol 76: 5472–5479. 50. Wada K, Aota S, Tsuchiya R, Ishibashi F, Gojobori T, et al. (1990) Codon usage tabulated from the GenBank genetic sequence data. Nucleic Acids Res 18 Suppl. pp 2367–2411. 51. Ako-Adjei D, Johnson MC, Vogt VM (2005) The retroviral capsid domain dictates virion size, morphology, and coassembly of gag into virus-like particles. J Virol 79: 13463–13472. 52. Ono A (2010) HIV-1 assembly at the plasma membrane. Vaccine 28 Suppl 2: B55–59. 53. Ono A (2007) Subcellular locations at which HIV-1 assembles. Uirusu 57: 9–18. HIV-1 Virus-Like Particles Production 54. Ono A, Ablan SD, Lockett SJ, Nagashima K, Freed EO (2004) Phosphatidy- linositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc Natl Acad Sci U S A 101: 14889–14894. 55. Bryant M, Ratner L (1990) Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A 87: 523–527. 56. Demirov DG, Freed EO (2004) Retrovirus budding. Virus Res 106: 87–102. 57. Hansen M, Jelinek L, Whiting S, Barklis E (1990) Transport and assembly of gag proteins into Moloney murine leukemia virus. J Virol 64: 5306–5316. 58. Jones TA, Blaug G, Hansen M, Barklis E (1990) Assembly of gag-beta- galactosidase proteins into retrovirus particles. J Virol 64: 2265–2279. 59. Ono A, Orenstein JM, Freed EO (2000) Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J Virol 74: 2855–2866. 60. Sandefur S, Varthakavi V, Spearman P (1998) The I domain is required for efficient plasma membrane binding of human immunodeficiency virus type 1 Pr55Gag. J Virol 72: 2723–2732. 61. Ono A, Freed EO (2004) Cell-type-dependent targeting of human immunode- ficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol 78: 1552–1563. 62. Kiernan RE, Ono A, Englund G, Freed EO (1998) Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol 72: 4116–4126. 63. Yuan X, Yu X, Lee TH, Essex M (1993) Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol 67: 6387–6394. 64. Ganser-Pornillos BK, Cheng A, Yeager M (2007) Structure of full-length HIV-1 CA: a model for the mature capsid lattice. Cell 131: 70–79. 65. Roy BB, Hu J, Guo X, Russell RS, Guo F, et al. (2006) Association of RNA helicase a with human immunodeficiency virus type 1 particles. J Biol Chem 281: 12625–12635. 66. Cantin R, Fortin JF, Lamontagne G, Tremblay M (1997) The presence of host- derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. J Virol 71: 1922–1930. 67. Fortin JF, Cantin R, Lamontagne G, Tremblay M (1997) Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 71: 3588–3596. PLoS ONE | www.plosone.org 13 Month 2011 | Volume 6 | Issue 11 | e28314